Zydus Lifesciences received the FDA go-ahead to manufacture paliperidone extended-release tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg. Shares of Zydus Lifesciences Ltd ended at ₹1,055, down by ₹10.15, or 0.95%, on the BSE.
Zydus Lifesciences received the FDA go-ahead to manufacture paliperidone extended-release tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg. Shares of Zydus Lifesciences Ltd ended at ₹1,055, down by ₹10.15, or 0.95%, on the BSE.